Skip to search formSkip to main contentSkip to account menu

sulthiame

Known as: sultiam, sultiame 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

AnticonvulsantsThiazines

Narrower (1)

Ospolot
Sulthiame:SCnc:Pt:Ser/Plas:Qn

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
Highly Cited
2014
Highly Cited
2014
Landau–Kleffner syndrome: A study of 29 patients
Highly Cited
2012
Highly Cited
2012
Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany—a nationwide population-based study in children and adults
Nationwide analyses of drug use can provide a prevalence estimate of the underlying disease and can help in understanding the… 
Review
2012
Review
2012
Sulfonamides: a patent review (2008 – 2012)
Introduction: The primary sulfonamide moiety is present in many clinically used drugs, such as diuretics (furosemide, indapamide… 
Highly Cited
2009
Highly Cited
2009
Clinical spectrum and medical treatment of children with electrical status epilepticus in sleep (ESES)
Purposes:  To describe the clinical spectrum and to evaluate the efficacy of different therapeutic agents in children with… 
Highly Cited
2005
Highly Cited
2005
Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain
Review
2005
Review
2005
Management of Landau-Kleffner Syndrome
Landau-Kleffner syndrome (LKS) is an acquired epileptic aphasia disorder in which children, usually 3–8 years of age who have… 
Highly Cited
2002
Highly Cited
2002
Carbonic Anhydrase Inhibitor Sulthiame Reduces Intracellular pH and Epileptiform Activity of Hippocampal CA3 Neurons
Summary:  Purpose: Sulthiame is a carbonic anhydrase (CA) inhibitor with an anticonvulsant effect in the treatment of benign and… 
Highly Cited
2000
Highly Cited
2000
Sulthiame as Monotherapy in Children with Benign Childhood Epilepsy with Centrotemporal Spikes: A 6‐Month Randomized, Double‐Blind, Placebo‐Controlled Study
Purpose: To evaluate the efficacy and tolerability of sulthiame (STM) as monotherapy in children with benign childhood epilepsy… 
Highly Cited
1968
Highly Cited
1968
Sulthiame (Ospolot®) as Inhibitor of Diphenylhydantoin Metabolism
The administration of sulthiame in doses of 200–800 mg daily to patients receiving diphenylhydantoin caused a rise in serum… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)